



EXPRESS MAIL NO.: EL615430294US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Rolf EHRHARDT, et al.

Appl. No.: 09/857,823

Filed: June 7, 2001

**ANIMAL MODEL FOR PSORIASIS FOR
THE PREVENTION AND TREATMENT OF
PSORIASIS IN HUMANS**

Art Unit: 2366

Examiner: Not Yet Assigned

Attorney Docket:
05882.0003.PCUS00

Supplemental Information Disclosure Statement

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not

10/22/2003 HROCHA1 00000019 09057823

01 FC:1806

100.00 DP

exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☐ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- 2. This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
 - c. Attached is our Check in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of

Allowance, but on or before payment of the Issue Fee. Attached is our Check in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p), and

- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☒ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents marked with an asterick were cited by or submitted to the Office in Application No. _____ filed _____ which is relied upon


for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 05882.0003.PCUS00.

Respectfully submitted,

Date: October 16, 2003


Albert P. Halluin (Reg. No. 25,227)
Robin C. Chiang (Reg. No. 46,619)


HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
(650) 463-8109



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 05882.0003.PCUS00	APPLICATION NO. 09/857,823
	APPLICANT Ehrhardt, <i>et al.</i>	
	FILING DATE June 7, 2001	GROUP 2366

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	5,578,707	11/26/1996	Rubinstein, <i>et al.</i>			
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	2.	EP 0 304 291	02/22/1989	EP			
	3.	EP 0 387 095	09/12/1990	EP			
	4.	EP 0 659 766	06/28/1995	EP			
	5.	EP Search Report 03001299.1	07/03/03	EP			
	6.	WO 00/32634	06/08/2000	PCT			
	7.	WO 92/11018	07/09/1992	PCT			
	8.	WO 96/34096	10/31/1996	PCT			
	9.	WO 97/37679	10/16/1997	PCT			
	10.	WO 98/28001	07/02/1998	PCT			
	11.	WO 99/09055	02/25/1999	PCT			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	12.	Landolfi, <i>et al.</i> , "The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody," <i>Journal of Immunology</i> , 166 (3):1748-1754 (2001)					
	13.	Prinz, <i>et al.</i> , "T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in-vitro via secreted products," <i>European Journal of Immunology</i> 24 (3):593-598 (1994)					
	14.						
	15.						
	16.						
	17.						
	18.						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



DO NOT ACCEPT THIS CHECK WITHOUT THE ARTIFICIAL WATERMARK ON THE REVERSE SIDE. HOLD AT ANGLE TO VIEW.

301 RAVENSWOOD AVENUE
MENLO PARK, CA 94025-3453

CITIBANK
CITIBANK, F.S.B.
ONE SANSONE STREET, 24TH FLOOR
SAN FRANCISCO, CA 94104

90-7118/396
3211

6298
006298

October 6, 2003

PAY ONE HUNDRED EIGHTY & NO/100

DOLLARS \$ 180.00

TO
THE
ORDER
OF

COMMISSIONER OF PATENTS &
TRADEMARKS

VOID AFTER 6 MONTHS

TWO SIGNATURES REQUIRED IF OVER \$1,000

⑈006298⑈ ⑆321171184⑆ 200017911⑈

DETACH AND RETAIN THIS STATEMENT. THE ATTACHED CHECK IS IN PAYMENT OF ITEMS DESCRIBED BELOW. IF NOT CORRECT PLEASE NOTIFY US PROMPTLY. NO RECEIPT DESIRED.

VENDOR NO.: 031516

VENDOR: COMMISSIONER OF PATENTS &

CHECK #: 006298

TOTAL: 180.00

Invoice: 05882AHI 10/06/03 Amount: 180.00

PDL/ANIMAL MODEL PSORIASIS

05882.0003.PCUS00

Fee to file Supplemental Information Disclosure Statement